2 terminated, 1 completed, 1 withdrawn. 4 Phase 2.
By phase and status
Follow Lumicitabine: new trials by email Literature Review of Lumicitabine trials Research Report on Lumicitabine
Trials (filtered) newest first · largest first
All 4 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus Lumicitabine, Placebo - Metapneumovirus Phase 2 Withdrawn 2018-11-05 2018-11-15
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection Lumicitabine, Placebo - Respiratory Syncytial Virus Infections Phase 2 Completed 7 2018-01-05 2021-04-13
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus Lumicitabine, Placebo - Respiratory Syncytial Viruses Phase 2 Terminated 7 2017-11-24 2019-12-23
Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus lumicitabine, Placebo - Respiratory Syncytial Viruses Phase 2 Terminated 49 2016-10-25 2019-12-24
Conditions studied Respiratory Syncytial Virus Infections (1)
Sponsors Janssen Research & Development, LLC (4)
Countries Japan (4) · Poland (3) · United States (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Bulgaria (2) · Canada (2) · France (2) · Malaysia (2) · Netherlands (2) · South Korea (2) · Spain (2) · Sweden (2)
Results publications PMID 37467213
NIH funding 2016 (2) , 2017 (2)